perioperative management of glp-1 agonists Don't miss the August ASA Monitor “Features” section for these articles and more: 🔸 Pop, Pause, or Pass? Navigating Preop Medications 🔸 Antihyperglycemic Medications 💊💊👉https://ow.ly/PmOQ50WxxZ6 Size:40 Servings Endocrine Research glp-1 obesity drug news

perioperative management of glp-1 agonists Don't miss the August ASA Monitor “Features” section for these articles and more: 🔸 Pop, Pause, or Pass? Navigating Preop Medications 🔸 Antihyperglycemic Medications 💊💊👉https://ow.ly/PmOQ50WxxZ6 Size:40 Servings Endocrine Research glp-1 obesity drug news

glp-1 obesity drug news today september 15 2025 2024 was a record year for trials and is already poised to take over glp-1 news september 30 2025 –

Retatrutide, Amycretin, Survodutide, VK2735, and MariTide are among the most watched pipeline assets heading into 2026 because each represents a different answer to the same commercial question: what comes after Ozempic, Wegovy, Mounjaro, and Zepbound

Endocrine Research

Size:40 Servings

They found rates of invasive recurrence and metastatic disease were high in both groups, but people using GLP-1s had a 74% lower risk of invasive or metastatic cancer progression